FDA warns Lifescan recall letter is misleading
This article was originally published in Clinica
Executive Summary
The US FDA says it is concerned that the product replacement programme, which the Johnson & Johnson subsidiary, Lifescan, implemented in June for its SureStep blood glucose meters, may cause both consumers and distributors to underestimate the seriousness of the recall.